Dr. John O. Schorge, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Vanderbilt University School of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 13
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Vanderbilt University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
MA license 153463 · NH license 14268 -
Obstetrics Physician
TN license 64958
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Regional One Health Memphis, TN
Medical groups
- Ut Regional One Physicians Inc (324 clinicians)
- Memphis Health Center, Inc. (17 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 13
- Services billed
- 25
- Patients’ average age
- 69
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 9 companies reported 22 payments worth $4,704 in total to this clinician.
| Intuitive Surgical, Inc. | $3,419 |
|---|---|
| Medtronic, Inc. | $516 |
| Coopersurgical, Inc. | $207 |
| Dilon Technologies, Inc. | $146 |
| Eisai Inc. | $143 |
| Biotissue Holdings Inc. | $124 |
| Ethicon US, LLC | $97.03 |
| Corcept Therapeutics | $26.43 |
| Travel and Lodging | $1,788 |
|---|---|
| Education | $1,500 |
| Food and Beverage | $1,416 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Intuitive Surgical, Inc. Jun 25, 2025 | Education DAVINCI XI · SURGERY · in-kind | $1,500 |
| Intuitive Surgical, Inc. May 22, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind | $540 |
| Intuitive Surgical, Inc. Apr 9, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind | $525 |
| Intuitive Surgical, Inc. Apr 23, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind | $353 |
| Intuitive Surgical, Inc. Apr 24, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind | $160 |
| Intuitive Surgical, Inc. Apr 25, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind | $160 |
| Intuitive Surgical, Inc. Apr 9, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind | $30.00 |
| Intuitive Surgical, Inc. May 22, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind | $19.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $23,209 in research payments for these studies, mostly to the institutions running them.
- PSR - Surgical
Medtronic, Inc. - A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Karyopharm Therapeutics Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.